Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Oral Pathol Med ; 31(9): 534-8, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12269992

RESUMO

BACKGROUND: Mutations in TP53 have been observed in a variety of tumors including oral lesions, though there are no reports in ameloblastomas. The purpose of the study was to examine the TP53 status of ameloblastomas using newly developed yeast functional assay whose accuracy and sensitivity has been proven to be higher than those of the previous DNA structure-based methods such as single strand conformation polymorphism (SSCP) analysis. METHODS: TP53 status was analyzed by yeast functional assay and DNA sequencing in 12 cases of ameloblastoma which were diagnosed histologically and represented the clinical features of a benign tumor. After the extraction of RNA from the frozen tissue samples without microdissection, reverse transcription (RT)-PCR was carried out and these samples were used. The assay can detect mutations of p53 mRNA between codons 67 and 347 by the DNA-binding activity of the protein and reveal them as red colonies. RESULTS: One case of 47-year-old male gave 17% red colonies of yeast and the other 11 cases gave 5.4% (mean; range, 3-8%). To confirm this result, we obtained other nine samples from the case of 17% red colonies, which contained or did not contain tumor tissues, and analyzed them by the assay. Seven samples that were histologically negative for tumor cells gave 4.7% red colonies (mean; range, 1-7%). Two samples that were histologically positive for tumor cells gave 20 or 46% of red colonies. The p53 plasmids were recovered from the red colonies of these three samples showing high red colony ratios and were subjected to sequencing analysis after purification. In all these samples, the same clonal mutation of TGT (Cys) 238 TAT (Tyr) was demonstrated. CONCLUSIONS: These results suggest that TP53 mutation may be involved in molecular pathogenesis in a subset of ameloblastomas, though it is infrequent.


Assuntos
Ameloblastoma/genética , Genes p53/genética , Neoplasias Bucais/genética , Adolescente , Adulto , Idoso , Substituição de Aminoácidos , Bioensaio , Análise Mutacional de DNA , Feminino , Genes Reporter , Humanos , Masculino , Pessoa de Meia-Idade , Mutação de Sentido Incorreto , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Saccharomyces cerevisiae/genética , Transcrição Gênica , Tirosina/genética
2.
Cancer Lett ; 175(1): 95-106, 2002 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-11734341

RESUMO

We investigated the effects of transforming growth factor-beta (TGF-beta) on biological behavior of a weakly malignant rat mammary carcinoma ER-1 cell line. TGF-beta enhanced the tumorigenic and metastatic capacity of ER-1 cells and their in vitro invasiveness to rat mesothelial and endothelial cell. Further cell biological analysis indicated that the increased invasive and metastatic capacity of ER-1 cells by TGF-beta was due to the increase in cell motility and adhesion to the mesothelial and endothelial cell monolayers. Thus, it is suggested that TGF-beta acts on ER-1 cells as a progression-enhancing factor which stimulates their adhesive and motile activities.


Assuntos
Neoplasias Mamárias Experimentais/patologia , Metástase Neoplásica/patologia , Fator de Crescimento Transformador beta/farmacologia , Proteínas de Xenopus , Animais , Anticorpos/farmacologia , Adesão Celular/efeitos dos fármacos , Moléculas de Adesão Celular/genética , Movimento Celular/efeitos dos fármacos , Quimiotaxia/efeitos dos fármacos , Proteínas de Ligação a DNA , Relação Dose-Resposta a Droga , Feminino , Receptores de Hialuronatos/imunologia , Ácido Hialurônico/farmacologia , Hialuronoglucosaminidase/farmacologia , Proteínas Imediatamente Precoces/genética , Cinética , Camundongos , Invasividade Neoplásica , Proteínas Nucleares/genética , Transativadores/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...